tbuckley/cabot-search huggingface dataset:
Cardiopulmonary Resuscitation
Authors: Rose A. Gates
Journal: Annals of Internal Medicine (1989)

Letters and Corrections15 October 1989Cardiopulmonary ResuscitationRose A. Gates, RN, MSN, Robert H. Gates, MDRose A. Gates, RN, MSNSearch for more papers by this author, Robert H. Gates, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-8-686 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Murphy and colleagues (1) recently described the outcomes of cardiopulmonary resuscitation in a retrospective review of 505 elderly patients. Only 19 patients survived to hospital discharge after cardiopulmonary resuscitation, and half of these survivors had serious chronic sequelae. Not discussed at length, but equally disturbing, was the finding that only 14 patients had a documented discussion about resuscitation. Bedell and Delbanco, among (2) others, have reported similar findings. Clearly, a device (3) or mechanism is needed to ensure that a dialogue about resuscitation preferences will occur.In a preliminary study at Fitzsimons Army Medical Center, a 450-bed...References1. MurphyMurrayRobinsonCampion DABE. Outcomes of cardiopulmonary resuscitation in the elderly. Ann Intern Med. 1989;111:199-205. LinkGoogle Scholar2. BedellDelbanco ST. Choices about cardiopulmonary resuscitation in the hospital. When do physicians talk with patients? N Engl J Med. 1984;310:1089-93. CrossrefMedlineGoogle Scholar3. Stephens R. "Do not resuscitate" orders. Ensuring the patient's participation. JAMA. 1986;244:240-1. CrossrefGoogle Scholar4. . American College of Physicians ethics manual. Part 2: the physician and society; research; life-sustaining treatment; other issues. Ann Intern Med. 1989;111:327-35. LinkGoogle Scholar1. MurphyMurrayRobinsonCampion DABE. Outcomes of cardiopulmonary resuscitation in the elderly. Ann Intern Med. 1989;111:199-205. LinkGoogle Scholar2. Podrid P. Resuscitation in the elderly: a blessing or a curse? Ann Intern Med. 1989;111:193-5. LinkGoogle Scholar3. Swender P. Reflections on the New York do-not-resuscitate law. NY State J Med. 1989;89:57-8. MedlineGoogle Scholar4. Callahan D. Setting Limits. New York: Simon and Schuster; 1987. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Fitzsimons Army Medical Center Aurora, CO 80045 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPatient acceptance of an information sheet about cardiopulmonary resuscitation options 15 October 1989Volume 111, Issue 8Page: 686-687KeywordsCardiopulmonary resuscitationElderlyResuscitation Issue Published: 15 October 1989 PDF DownloadLoading ...
Health Initiatives
Authors: Mike Mitka
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SURGICAL SHOCK.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins
Authors: Delphine Mérino, Maybelline Giam, Peter D. Hughes, Owen M. Siggs, Klaus Heger, Lorraine A. O'Reilly, Jerry M. Adams, Andreas Strasser, Erinna F. Lee, Walter D. Fairlie, Philippe Bouillet
Journal: The Journal of Experimental Medicine (2009)
Leukocytes and the risk of ischemic diseases
Authors: E. Ernst
Journal: JAMA (1987)

Predictive indexes for atherosclerotic risk are imperfect, suggesting that there are predictive factors not commonly considered. Such a factor may be the white blood cell (WBC) count. Epidemiologic studies have shown correlations between the WBC count and the risk of myocardial infarction and stroke. The risk of acute myocardial infarction is approximately four times as great in persons with WBC counts high in the normal range (&gt;9000/μL [9 × 10<sup>9</sup>/L]) as in persons with WBC counts low in the normal range (&lt;6000/μL [6 × 10<sup>9</sup>/L]); only 50% to 65% of the excess risk of the high-count individuals is explainable by tobacco smoking (which covaries with WBC count). A high WBC count also predicts greater risk of reinfarction and of in-hospital death. Less rigorously studied, the constitutional neutropenia of Yemenite Jews appears to afford protection against atherosclerotic disease. Among WBC types, the strongest epidemiologic association has been with the neutrophil count. Such a predictive value of WBC count is plausible and satisfying, because WBCs (<i>a</i>) make a major contribution to the rheologic properties of blood; (<i>b</i>) alter adhesive properties under stress— including the stress of ischemia, enhancing their rheologic importance; and (<i>c</i>) participate in endothelial injury, both acutely and chronically, by adhering to endothelium and damaging it with toxic oxygen compounds and proteolytic enzymes. Techniques newly developed or under development may allow us to refine the predictive value of the WBC count by combining it with measures of cell activation and/or activatability. (<i>JAMA</i>1987;257:2318-2324)
Abstract 1770: RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation
Authors: Ke Yao, Sung-Young Lee, Cong Peng, Do Young Lim, Hiroyuki Yamamoto, Joohyun Ryu, Tae-Gyu Lim, Hanyong Chen, Wei-Ya Ma, Ann M. Bode, Zigang Dong
Journal: Cancer Research (2019)

Abstract Inflammation is a complex biological host reaction to tissue damage, infection and trauma. Extensive study of the inflammatory response has led to the identification of several protein kinases that are essential for signaling and could be potential therapeutic targets. The RSK family of kinases has multiple cellular functions. In our study, we found that RSK2 is a mediator for inflammation signaling and interacts with TRAF6. In vitro kinase assay results indicated that RSK2 strongly phosphorylates TRAF6 at serines 46, 47 and 48. Ectopic over-expression of TRAF6 or knocking down RSK2 expression confirmed that RSK2 is a positive regulator of TRAF6 K63 ubiquitination. TRAF6 is also required for RSK2 ubiquitination. TRAF6 bridges the TNF receptor superfamily and intracellular signaling for the induction of pro-inflammatory cytokines. We developed a colon inflammation model using RSK2 wild type (WT) and knockout (KO) mice. As expected, F4/80 and CD3 infiltration were significantly upregulated in WT mice compared to RSK2 KO mice. Furthermore, inflammation signaling, including Ikkα/β, p38 and JNKs, was dramatically up-regulated in WT mice. Colon tissue immunoprecipitation results further confirmed that TRAF6 K63 ubiquitination was lower in RSK2 KO mice. Overall, these results indicate that phosphorylation of TRAF6 (S46, 47, 48) by RSK2 is required for TRAF6 K63 ubiquitination and inflammation signaling. Citation Format: Ke Yao, Sung-Young Lee, Cong Peng, Do Young Lim, Hiroyuki Yamamoto, Joohyun Ryu, Tae-Gyu Lim, Hanyong Chen, Wei-Ya Ma, Ann M. Bode, Zigang Dong. RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1770.
29. Immunization
Authors: Edina H Moylett, I Celine Hanson
Journal: Journal of Allergy and Clinical Immunology (2003)

<h2>Abstract</h2> The medical dictionary defines immunization as the "protection of susceptible individuals from communicable diseases by the administration of a living modified agent, a suspension of killed organisms, or an inactivated toxin." This elegant description can be expanded to include twenty-first century approaches to immunization that include recombinant technology, reassortment virus techniques, live vectors, DNA vaccines, and the expansion of the field to encompass noncommunicable diseases such as Alzheimer's disease, autoimmunity, and tumor immunogenetics. Integral to the success of immunization is our knowledge of the immune system's memory of antigens, yet our understanding of this fundamental feature remains limited. On a global scale, communicable diseases remain the number-one cause of morbidity and mortality; hence Jenner's pioneering work with its birth in 1796 still has a challenging and exciting future. (J Allergy Clin Immunol 2003;111:S754-65.)
Manuscripts Approved for JNCI, August 1 to September 1, 1967
Journal: JNCI Journal of the National Cancer Institute (1967)

Journal Article Manuscripts Approved for JNCI, August 1 to September 1, 1967 Get access JNCI: Journal of the National Cancer Institute, Volume 39, Issue 4, October 1967, Pages 791–792, https://doi.org/10.1093/jnci/39.4.791-a Published: 01 October 1967
MA 06.09 Detection of EGFR T790M Mutations by Four Testing Platforms in ctDNA from Chinese Patients with Advanced NSCLC
Authors: X. Zhang, Z. Liang, Y. Chen, H. Zhang, G. Wu, Y. Lu, Z. Liang, Y. Cheng, Y. Hu, J. Wang, J. Ying, W. Liu, Y. Wu
Journal: Journal of Thoracic Oncology (2017)
Implants eyed for CMV retinitis
Authors: P. Cotton
Journal: JAMA (1993)

TEN YEARS ago, patients with the acquired immunodeficiency syndrome (AIDS) who developed cytomegalovirus (CMV) retinitis lived, on average, 2 months. Now that such patients survive more than 1 year on average, and some up to 3 years, the need for better therapy is becoming urgent. Implants that release drugs directly in the eye may help, says Jay S. Duker, MD, associate professor of ophthalmology at Tufts University Medical School, Boston, Mass. Phase III trials are now getting under way. The idea, he says, is to get higher levels of drug directly into the eye without the side effects of systemic absorption. Cytomegalovirus kills retinal cells that do not regenerate, leaving scotomata (blind spots), and eventually causing complete blindness by destroying the entire retina, causing retinal detachment or optic nerve damage. <h3>Number One Eye Problem</h3> Cytomegalovirus retinitis is the number one eye problem in AIDS. About 25% of patients with AIDS
Tony Jackson
Authors: Tony Jackson
Journal: BMJ (2006)

Paediatrician who became a pioneer in the management of cystic fibrosisTony Jackson made a considerable contribution to the transformation of cystic fibrosis from a fatal disease of infancy to a chronic disease of adults.He applied the developing technology and pharmaceutical developments to everyday practice, supported families and patients, and, after retirement, gave strategic direction to the Cystic Fibrosis Trust research and medical advisory committee, of which he was chairman.The trust awarded him its John Panchaud medal.
Care and training of handicapped children.
Journal: BMJ (1968)

hazard relates to wood dusts generally or only to the dusts from specific woods.In other parts of the world, notably China, Malaysia, Indonesia, and East Africa, nasopharyngeal cancer is more frequent than in the United Kingdom.3It seems unlikely, however, that the aetiological factors in these areas, such as incense smoke,' smoke from domestic wood fires,5 and racial,6 anatomical,' nutritional,7 or possibly hormonal8 9
Le disque intervertébral: Physiologie, pathologie, indications thérapeutiques.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Superselective Angiography
Authors: Oscar Sugar
Journal: JAMA (1978)

One of the burgeoning costs of medical treatment is that of radiography. Yet through recent advances in the field (p 1283), it is now possible radiologically to visualize minute ramifications of branches of the arterial tree. To attain this achievement has required costly research and apparatus, and to apply the new techniques to diagnosis and treatment is unquestionably expensive. But see what it gives in return! Patients, otherwise normal, who have disfiguring congenital malformations of the face and head now can be examined and treated. Radiological techniques permit us not only to look at the blood supply to these lesions but also to occlude or embolize these vessels of supply with the use of pledgets of gelatin foam or plastic globules. Such treatment can, by itself, produce a shrinkage in size and color of angiomas of the face and tongue, an alteration that can bring peace of mind and improvement
Drug-resistant malaria raises concern, controversy
Authors: H. Carswell
Journal: JAMA (1983)

The unrelenting spread of resistance to drugs used for prophylaxis of<i>Plasmodium falciparum</i>malaria, the most virulent of the four species affecting humans, has become a focus of increasing concern, according to experts from the Centers for Disease Control (CDC) in Atlanta. Reports to the annual meeting of the American Society for Tropical Medicine and Hygiene, held recently in Cleveland, indicate that Americans traveling to the East African countries of Kenya, Tanzania, Uganda, Madagascar, Mozambique, and the Comoro Islands are at particular risk for slipping through the veil of drug protection and acquiring the illness. These findings prompted a recent revision of the CDC's recommended prophylaxis policy for<i>P falciparum</i>in visitors to these regions, according to Malaria Branch chief C. C. Kent Campbell, MD (<i>MMWR</i>1982;31:No. 24 [June 25]). Despite the advisory, however, new cases of malaria among US travelers continue to be reported. (One pair of researchers has determined
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF<sub>V600E/K </sub>mutant advanced or metastatic melanoma (MM).
Authors: Caroline Robert, Keith T. Flaherty, Peter Hersey, Paul D. Nathan, Claus Garbe, Mohammed M. Milhem, Lev V. Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James M. G. Larkin, Jochen Utikal, Michelle Casey, Laurie Jill Sherman, Wendy A. Crist, Frank S. Wu, Kiran Patel, Dirk Schadendorf
Journal: Journal of Clinical Oncology (2012)

LBA8509 Background: Dacarbazine (D) and paclitaxel (P) have been used to treat MM pts with limited effect. The MM treatment landscape has recently changed with the approval of vemurafenib and ipilimumab in 2011, but secondary malignancies or other toxicities are of concerns. T is a reversible, highly selective allosteric inhibitor of MEK1/2 activation and kinase activity. In a PhII trial (NCT01037127), pts with BRAFV600E mutation MM had median PFS of 5.3 mos. This PhIII trial (NCT01245062) was conducted in pts with BRAFV600E/K mutant advanced or MM. Methods: Pts were randomized 2:1 to T (2mg QD) or C (D or P). Pts were stratified by baseline LDH level and prior C; pts in the C arm were allowed to crossover to receive T after confirmation of PD. Primary endpoint was PFS in pts with BRAFV600E mutation-positive MM and no prior brain mets; secondary endpoints were OS, ORR and safety in primary and ITT. PFS and OS were compared using a stratified log-rank test. The study was designed with ≥99% power and one-sided α = 0.025 to detect 57% reduction in the risk of PD or death in pts treated with T vs C. Results: Between Dec 2010 and Jul 2011, 322 pts were randomized to T (n=214) or C (n=108); 273 pts were BRAFV600E mutation-positive with no prior brain mets. HR for primary population for PFS by investigator was 0.44 (95% CI 0.31–0.64; p&lt;0.0001) in favor of T with a median PFS of 4.8 mo vs 1.4 mo with C. PFS benefit in favor of T was observed in ITT; this was confirmed by an independent review. The confirmed ORR was 24% with T and 7% with C. HR for interim OS was 0.53 (95% CI 0.30–0.94; p=0.0181), in favor of T in primary population. OS benefit was consistent in ITT pop despite 51 pts crossover from C to T. The most frequent AEs with T were skin rash, diarrhea, edema, hypertension, fatigue. Known MEKi class effects were observed, e.g. chorioretinopathy (&lt;1%) and decreased ejection fraction (7%). Grade 3 AEs in T arm were hypertenstion (12%) and rash (7%). Conclusions: T is the first in class MEKi associated with a significant improvement of PFS and OS compared to C in pts with BRAF V600E/K mutant MM.
Incorrect Data in Text, Table, and Figure Legend
Authors: Regis Goulart, Maicon Falavigna, Cassiano Teixeira
Journal: JAMA (2019)

Anil K. Chaturvedi, PhD; Barry I. Graubard, PhD; Tatevik Broutian, PhD; Weihong Xiao, MD; Robert K. L. Pickard, MS; Lisa Kahle, BA; Maura L. Gillison, MD, PhD
Articular and cutaneous sporotrichosis
Authors: J. W. Manhart
Journal: JAMA (1970)

A patient with chronic granulocytopenia and marrow hypoplasia of unknown etiology developed articular and cutaneous sporotrichosis while receiving corticosteroid therapy. The patient's active participation in gardening is presumably the major factor in the development of this mycotic infection. We postulate that the chronic granulocytopenia and corticosteroid administration contributed to the dissemination of the disease and the resulting articular involvement.
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
Authors: Victor H Jimenez-Zepeda, Christopher P. Venner, Andrew Belch, Irwindeep Sandhu, Tatiana Nikitina, Joanne D Hewitt, Peter Duggan, Paola Neri, Fariborz Rashid-Kolvear, Nizar J Bahlis
Journal: Blood (2015)
Differential HBV RNA and quantitative HBsAg kinetics between HBeAg(+) and HBeAg(−) patients with chronic hepatitis B on nucleos(t)ide analogues (NA)
Authors: Pir Ahmad Shah, Rizwan Ishtiaq, Satinder Pal Kaur, Jeffrey Gersch, Saad Choudhry, Mary Kuhns, Gavin Cloherty, Daryl Lau
Journal: Journal of Hepatology (2020)
Lung biopsy
Authors: S. J Steel
Journal: BMJ (1985)

<h3>Abstract</h3> In times of global biodiversity crisis, developing tools to define, quantify, compare and predict ecological resilience is essential for understanding species’ responses to global change. Disparate interpretations of ecological resilience have, however, hampered the development of a common currency to quantify and compare resilience across natural systems. Most frameworks of study have focused on upper levels of biological organisation, especially ecosystems or communities, which adds layers of complication to measuring resilience with empirical data. To overcome such limitations, we suggest quantifying resilience using demographic data. Surprisingly, a quantifiable definition of resilience does not exist at the demographic level. Here, we present a framework of demographic resilience with a set of metrics that are comparable across species, and facilitate cost-effective management decisions.
Association of acromegaly and meningiomas
Authors: E. M. Bunick
Journal: JAMA (1978)

THE SIMULTANEOUS occurrence of an intracranial meningioma and a pituitary adenoma is exceedingly rare, with only six cases previously reported.<sup>1-2</sup>In two of those cases, both tumors were present before therapy. Since the meningiomas developed after radiation therapy in the other four cases, the possibility must be considered that growth hormoneproducing pituitary tumors facilitate the development of meningiomas. We report the coexistence of a growth hormone-producing pituitary tumor and a subfrontal meningioma at the time of initial diagnosis. <h3>Report of a Case</h3> A 57-year-old man was admitted to Hahnemann Medical College and Hospital for evaluation of an abnormal skull roentgenogram and acromegalic features. The patient had intermittent right-sided headaches unaccompanied by change in vision, nausea, or vomiting precipitated by anxiety. For many years, these were promptly relieved by acetaminophen. Though his hands had always been large, his feet had increased in size during the years. He denied any change